Brief: CStone Pharmaceuticals Enters Licensing Agreement With Shenyang Sunshine Pharmaceutical
01/11/2023 10:34
Nov 1 (Reuters) - CStone Pharmaceuticals 2616.HK :
* STRATEGIC PARTNERSHIP AND EXCLUSIVE LICENSING AGREEMENT
WITH
SHENYANG SUNSHINE PHARMACEUTICAL
* AGREEMENT FOR NOFAZINLIMAB (ANTI-PD-1 ANTIBODY) IN
MAINLAND
CHINA
* UNDER TERMS OF AGREEMENT, CSTONE WILL RECEIVE AN UPFRONT
PAYMENT
OF RMB60 MILLION
* UNDER AGREEMENT, DEVELOPMENT AND REGISTRATION MILESTONE
PAYMENTS
WILL REACH RMB100 MILLION
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026